Invitae Jefferson Population Health Workshop

"Genome Management for Life: Vision or Reality"

1



THE FOURTEENTH POPULATION HEALTH COLLOQUIUM

"Population Health and patient-centered care are at the heart of the Affordable Care Act (ACA)."

"All of the stakeholders across the health care ecosystem must be prepared to collaborate and integrate at an unprecedented level to achieve meaningful changes that will improve patient outcomes."

"Population-based medicine and wellness and prevention are squarely at the forefront of health care".

Today's Workshop Agenda

- Objectives and Goals of Today's Workshop
- Overview: Invitae Corporation
- "Genome Management for Life: Vision or Reality" Presentations and Group Discussion
- Wrap-up: Summary of Recommendations and Next Steps

Objectives and Goals of Today's Workshop

- Understand the challenges and opportunities that exist for diagnosis/prevention/wellness programs built around genetics in population-health directed programs.
- Understand the factors influencing the use of genetic testing in clinical decision making and integration into existing healthcare systems.
- Discuss how "genome management" can be developed and incorporated into a population health program and be utilized as a successful tool for the health management of individuals.
- Gain a better understanding from today's workshop attendees on current and future best practices for a genomic management partner such as Invitae to contribute to successful population health programs.

Today's Workshop

- Today's meeting should be as interactive as possible.
- The agenda is designed for you to provide us your feedback on issues critical to the future development of a successful population health genome management program. Everyone should be an active participant.
- Please share with us your ideas throughout the workshop on additional resources and clinical information you feel we can provide to support a successful genome management program.
- Thank you for participating today. Your opinion and experience are key to the development of a successful genome management program. We will follow-up on each of the ideas and questions generated from today's discussion.



Corporate Overview Jefferson Population Health Workshop March 2014

Stan Skrzypczak Business and Corporate Development bd@invitae.com

Invitae Background

Invitae, a genetics information company, has raised \$87 million in capital to bring comprehensive genetic information into routine medical practice.

•More than 100 people reinventing the genetic testing business

•First-in-kind commercial product launch Nov. 19, 2013 – 218 genes - \$1,500

Principal investors

- Baker Brother Investments
- Thomas McNerney Partners
- Randy Scott
- Genomic Health
- Genesys Capital
- Casdin Capital
- Redmile

A team with unparalleled experience

Lisa Alderson, Commercial Disney, Crossloop, Genomic Health

Lee Bendegkey, Finance & Legal Incyte, Nuvelo, DNAnexus

Michele Cargill, Science & Genetics Navigenics, Affymetrix, Celera

Alex Furman, Software Development Navigenics, Iris Financial Solutions

Sean George, Technology & Development Navigenics, Affymetrix, Invitrogen

Jill Hagenkord, Medical Complete Genomics

Steve Lincoln, Informatics Complete Genomics, Affymetrix, Incyte

Randy Scott, Strategy Genomic Health, Incyte

Jon Sorenson, Bioinformatics Pacific Biosciences, Applied Biosystems

e affymetrix





Senomic Health

illumına[®]









Our long term vision


what:

To bring comprehensive genetic information into routine medical practice to improve the quality of healthcare for billions of people

how:

By aggregating the world's genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today

Population-based genetic testing is already widely used



"Genome Management for Life: Vision or Reality" Discussion Topics

- Introduction and Program Overview:
 - Stan Skrzypczak, MS, MBA, Vice President of Business Development, Invitae
- Towards Precision Medicine: Moving from Illness to Wellness
 - Steven Tucker, MD, Novena Specialist Center, Singapore
- Practical Considerations for the Delivery and Use of Genetics in Routine Care with New Technologies:
 - Patrick Terry, CEO, Grey Group Ventures
- Genome Management and It's Relationship to Population Health:
 - Randy Scott, PhD, CEO and Co-founder Invitae
- Moderated Discussion:
 - Led by Stan Skrzypczak, Invitae

A Case Study Exemplifying "Genome Management"

- Female ~45y, presenting with breast cancer
- BRCA1/2 Negative
- Consented to biobank a blood sample ~8 years ago

- In this study, shown to be MLH1 positive (Lynch)
- Re-contacted: She had Dx of endometrial cancer in the intervening period
- Additional colonoscopy performed: Positive (polyps found and removed)

	ΙΝΥΙΤΛΕ			Nam_PA1	e IENT_NAME_	DO8_ _DO8_
Patient Name	s	DOB:	Gender:	MRN:	InVit	àe#:
Physician		Report Date	Sample Type	Ancestry:	Date	Received
Test indication Breast Cancer	1		Previous Results			
Test Performe Sequence analy	d rsis of the genes listed in the table below.		BRCA1/2 negative			
Summary						
Comment	genic sequence chang ome (MLH1)					
tor	athogenic sequence change was iden the and Turcot syndromes are primar these conditions is strongly recomme ille breast capacity because the	and I at a	a b) colon, endor	rietrial and CNS to	imors. Follow.	UD evaluation
• Wh pre • Gei ww	ich and Turcoi syndromes are primar these conditions is strongly recomm- lie breast cancer has been reported in sentation. It is therefore not clear if t netic counseling is advised to discuss w.nsgc.org.	ended. This pa n patients with	tient is at risk for Lynch Syndrome,	developing Lynch isolated breast ca	syndrome.	up evaluation
• Wh pre • Gei ww	these conditions is strongly recomme ile breast cancer has been reported in sentation. It is therefore not close if a	ended. This pa n patients with this sequence cl the implication	tient is at risk for Lynch Syndrome,	developing Lynch isolated breast ca	syndrome.	up evaluation most common , please visit
for Wh pre Ger www tesults	these conditions is strongly recomm lie breast cancer has been reported in sentation. It is therefore not clear if t netic counseling is advised to discuss w.nsgc.org. Condition Group Hereditary Cancers (Lynch)	ended. This pa n patients with this sequence cl the implication Varian C.219	to color, endo ient is at risk for Lynch Syndrome, hange explains th is of this result. F t Name odelT	Vertilia and CNS ti developing Lynch isolated breast ca is patient's report for a listing of gen Protein Effect Pro731Leu_fs*52	imors. Follow- Syndrome. incer is not the ed condition. etic counselors	up evaluation most common , please visit Variant Classification
tor • Wh pre • Gen Www Results Gene MLH1	threse conditions is strongly recommu- lie breast cancer has been reported in sentation. It is therefore not clear if t netic counseling is advised to discuss w.nsgc.org. Condition Group Hereditary Cancers (Lynch) The following genes w	ended. This pa n patients with this sequence cl s the implication Varian c.219 vere sequenced, and	tient is at risk for Lynch Syndrome, hange explains th ns of this result. F t Name odelT	Vertial and CNS ti developing Lynch isolated breast ca is patient's report for a listing of gen Protein Effect Pro731Leu_fs*52	Imors. Follow- Syndrome. Incer is not the ed condition. etic counselors Zygosity heterozygous	up evaluation most common , please visit Classification PATHOGENIC
tor • Wh pre • Gen www Results Gene MLH1 APC, BLM, BM	these conditions is strongly recomm lie breast cancer has been reported in sentation. It is therefore not clear if t netic counseling is advised to discuss w.nsgc.org. Condition Group Hereditary Cancers (Lynch) The following genes w APIA, BRCA1, BRCA2, BRIP1, CDH1, CDH7, CDK	ended. This pa n patients with i this sequence cli the implication c.219 vere sequence, and CN2A LIGC4. MEN, SMAD4, STK	ten is at risk for Lynch Syndrome, hange explains th is of this result. F t Name odelT only benign polymon MET, MSH2, MSH2, 1753, YHL	developing Lynch isolated breast ca is patient's report or a listing of gen Protein Effect Pro731Leu_fs*52 phisms were found: MUTYH, NBN, PALB2	Imors. Follow- Syndrome. Incer is not the ed condition. etic counselors Zygosity heterozygous	up evaluation most common , please visit Classification PATHOGENIC
Tor Wh pre Gene MLH1 APC, BLM, BM	threse conditions is strongly recommu- lie breast cancer has been reported in sentation. It is therefore not clear if t netic counseling is advised to discuss w.nsgc.org. Condition Group Hereditary Cancers (Lynch) The following genes w	ended. This pa n patients with i this sequence cli the implication c.219 vere sequence, and CN2A LIGC4. MEN, SMAD4, STK	ten is at risk for Lynch Syndrome, hange explains th is of this result. F t Name odelT only benign polymon MET, MSH2, MSH2, 1753, YHL	developing Lynch isolated breast ca is patient's report or a listing of gen Protein Effect Pro731Leu_fs*52 phisms were found: MUTYH, NBN, PALB2	Imors. Follow- Syndrome. Incer is not the ed condition. etic counselors Zygosity heterozygous	up evaluation most common , please visit Classification PATHOGENIC

Genetic testing has the largest market possible... everyone on the planet.

